Mr. Carroll served in a number of top roles at Boehringer Ingelheim including Head, Global Strategy and Development and Managing Director, President and Chief Executive Officer, U.S. from 2003 through 2011. During his tenure, Mr. Carroll was instrumental in guiding the launch of Spiriva ® and Pradaxa ® in the U.S. In addition, he was involved in the diabetes market through BI's partnership with Eli Lilly and the launch of Tradjenta ®, a novel option for treating type 2 diabetes. Mr. Carroll played a major role in working with the BI board of managing directors to develop strategic approaches for a number of BI businesses, focusing mainly on pharmaceuticals.Dr. Plutzky is Director of the Vascular Disease Prevention Program, which includes the Lipid/Prevention Clinic, in the Cardiovascular Medicine Division at Brigham and Women's Hospital, a role he has held since 1996. He is internationally recognized as an expert in both the basic science and clinical issues related to lipid disorders and cardiometabolic disease. Dr. Plutzky is known particularly for his broad interdisciplinary background that spans endocrinology and cardiology, and for his extensive experience with biotechnology and pharmaceutical concerns, as well as regulatory affairs. He is a member of the scientific advisory boards of the Sarnoff Cardiovascular Research Foundation and Ember Therapeutics, and he has also been elected to the American Society for Clinical Investigation.
VIVUS Mails Letter To Stockholders Providing Business Update
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts